Table 3.
Base Case Results From the Cost‐Effectiveness Analysis
| iECG | Usual care | Difference | ES* | ICER | |
|---|---|---|---|---|---|
| Total cost | $31 196 | $31 095 | $101 | 0.002 | |
| Management | $22 238 | $22 240 | −$3 | … | |
| Rehabilitation | $5506 | $5717 | −$211 | … | |
| Hospitalization | $2792 | $2888 | −$96 | … | |
| NOAC | $563 | $222 | $342 | … | |
| Adverse events | $70 | $28 | $43 | … | |
| iECG device | $27 | $0 | $27 | … | |
| No. of recurrent stroke † | 0.344 | 0.358 | −0.014 | 0.019 | $7374 |
| No. of stroke‐related death † | 0.064 | 0.066 | −0.002 | 0.008 | $56 275 |
| QALY | 6.697 | 6.663 | 0.034 | 0.012 | $3013 |
| LY | 11.51 | 11.47 | 0.037 | 0.008 | $2733 |
ES indicates effect size (calculated as standardized mean difference); ICER, incremental cost‐effectiveness ratio; iECG, smartphone‐based handheld ECG device; LY, life‐year; NOAC, new oral anticoagulant; and QALY, quality‐adjusted life‐year.
*
The average number of events across all simulated cohort since not all patients would experience an event over the modeled time horizon.
†
Effect size <0.1 is considered trivial.